Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Axsome Therapeutics announces anticipated milestones » 07:09
05/08/20
05/08
07:09
05/08/20
07:09
AXSM

Axsome Therapeutics

$91.37 /

+0.98 (+1.08%)

Anticipated Milestones:…

Anticipated Milestones: NDA Submissions: AXS-05 in the treatment of MDD 4Q 2020; AXS-07 in the acute treatment of migraine 4Q 2020. FDA Meetings: AXS-14 for fibromyalgia 2H 2020; AXS-05 for smoking cessation 2H 2020. Clinical Trial Initiations: Phase 3 trial of AXS-05 in TRD 3Q 2020; Phase 3 trials of AXS-12 in narcolepsy 2H 2020; Phase 3 trial of AXS-05 in Alzheimer's disease agitation 2H 2020.

ShowHide Related Items >><<
AXSM Axsome Therapeutics
$91.37 /

+0.98 (+1.08%)

04/28/20 Guggenheim
Axsome Therapeutics price target raised to $200 from $158 at Guggenheim
04/28/20 SunTrust
Axsome Therapeutics price target raised to $200 from $145 at SunTrust
04/28/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $131 from $125 at Cantor Fitzgerald
04/28/20 H.C. Wainwright
Axsome Therapeutics price target raised to $210 from $200 at H.C. Wainwright
Hot Stocks
Axsome Therapeutics expects cash to fund operations for at least two years » 07:07
05/08/20
05/08
07:07
05/08/20
07:07
AXSM

Axsome Therapeutics

$91.37 /

+0.98 (+1.08%)

Axsome believes that its…

Axsome believes that its cash at March 31, 2020 will be sufficient to fund the company's anticipated operations, based on its current operating plans, for at least two years.

ShowHide Related Items >><<
AXSM Axsome Therapeutics
$91.37 /

+0.98 (+1.08%)

04/28/20 Guggenheim
Axsome Therapeutics price target raised to $200 from $158 at Guggenheim
04/28/20 SunTrust
Axsome Therapeutics price target raised to $200 from $145 at SunTrust
04/28/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $131 from $125 at Cantor Fitzgerald
04/28/20 H.C. Wainwright
Axsome Therapeutics price target raised to $210 from $200 at H.C. Wainwright
Earnings
Axsome Therapeutics reports Q1 EPS (88c), consensus (62c) » 07:07
05/08/20
05/08
07:07
05/08/20
07:07
AXSM

Axsome Therapeutics

$91.37 /

+0.98 (+1.08%)

"The recent clinical…

"The recent clinical successes in our late-stage pipeline, including positive efficacy data in depression, Alzheimer's disease agitation, migraine, narcolepsy, and fibromyalgia, highlight Axsome's accelerated evolution into a leading, innovative CNS company," said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. "The ability to tackle unmet medical needs in these serious and difficult-to-treat CNS diseases, underscores the importance of our novel investigational medicines. As we move towards the submission of two NDAs in the fourth quarter, one for AXS-05 in depression and one for AXS-07 in migraine, our commercial team is focused on launch-readiness activities to ensure successful commercial execution. In parallel, we look to continue the momentum in our other late-stage development programs, including AXS-05 in Alzheimer's disease agitation, for which we intend to meet with the FDA after the recently announced positive ADVANCE-1 pivotal trial results in this indication, and AXS-12 in narcolepsy, for which we remain on track to initiate Phase 3 trials later this year."

ShowHide Related Items >><<
AXSM Axsome Therapeutics
$91.37 /

+0.98 (+1.08%)

04/28/20 Guggenheim
Axsome Therapeutics price target raised to $200 from $158 at Guggenheim
04/28/20 SunTrust
Axsome Therapeutics price target raised to $200 from $145 at SunTrust
04/28/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $131 from $125 at Cantor Fitzgerald
04/28/20 H.C. Wainwright
Axsome Therapeutics price target raised to $210 from $200 at H.C. Wainwright
Over a month ago
Conference/Events
SunTrust to hold a virtual summit » 04:55
05/06/20
05/06
04:55
05/06/20
04:55
HOOK

Hookipa Pharma

$8.90 /

+0.45 (+5.33%)

, AXSM

Axsome Therapeutics

$90.35 /

-1.35 (-1.47%)

, VKTX

Viking Therapeutics

$6.69 /

+0.35 (+5.52%)

6th Annual Life Sciences…

6th Annual Life Sciences Virtual Summit 2020 will be held on May 5-6.

ShowHide Related Items >><<
HOOK Hookipa Pharma
$8.90 /

+0.45 (+5.33%)

09/27/19 H.C. Wainwright
Hookipa Pharma initiated with a Buy at H.C. Wainwright
05/13/19 BofA
Hookipa Pharma initiated with a Buy at BofA/Merrill
05/13/19 RBC Capital
Hookipa Pharma initiated with an Outperform at RBC Capital
AXSM Axsome Therapeutics
$90.35 /

-1.35 (-1.47%)

04/28/20 Guggenheim
Axsome Therapeutics price target raised to $200 from $158 at Guggenheim
04/28/20 SunTrust
Axsome Therapeutics price target raised to $200 from $145 at SunTrust
04/28/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $131 from $125 at Cantor Fitzgerald
04/28/20 H.C. Wainwright
Axsome Therapeutics price target raised to $210 from $200 at H.C. Wainwright
VKTX Viking Therapeutics
$6.69 /

+0.35 (+5.52%)

05/05/20 Chardan
Viking Therapeutics initiated with a Buy at Chardan
05/04/20 B. Riley FBR
Viking Therapeutics price target lowered to $12 from $16 at B. Riley FBR
05/01/20 BTIG
Viking Therapeutics initiated with a Buy at BTIG
02/27/20 H.C. Wainwright
Viking Therapeutics price target lowered to $18 from $31 at H.C. Wainwright
Conference/Events
SunTrust to hold a virtual summit » 08:55
05/05/20
05/05
08:55
05/05/20
08:55
HOOK

Hookipa Pharma

$8.45 /

+0.45 (+5.63%)

, AXSM

Axsome Therapeutics

$91.70 /

+1.6 (+1.78%)

, VKTX

Viking Therapeutics

$6.34 /

+0.91 (+16.76%)

6th Annual Life Sciences…

6th Annual Life Sciences Virtual Summit 2020 will be held on May 5-6.

ShowHide Related Items >><<
HOOK Hookipa Pharma
$8.45 /

+0.45 (+5.63%)

09/27/19 H.C. Wainwright
Hookipa Pharma initiated with a Buy at H.C. Wainwright
05/13/19 BofA
Hookipa Pharma initiated with a Buy at BofA/Merrill
05/13/19 RBC Capital
Hookipa Pharma initiated with an Outperform at RBC Capital
AXSM Axsome Therapeutics
$91.70 /

+1.6 (+1.78%)

04/28/20 Guggenheim
Axsome Therapeutics price target raised to $200 from $158 at Guggenheim
04/28/20 SunTrust
Axsome Therapeutics price target raised to $200 from $145 at SunTrust
04/28/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $131 from $125 at Cantor Fitzgerald
04/28/20 H.C. Wainwright
Axsome Therapeutics price target raised to $210 from $200 at H.C. Wainwright
VKTX Viking Therapeutics
$6.34 /

+0.91 (+16.76%)

05/05/20 Chardan
Viking Therapeutics initiated with a Buy at Chardan
05/04/20 B. Riley FBR
Viking Therapeutics price target lowered to $12 from $16 at B. Riley FBR
05/01/20 BTIG
Viking Therapeutics initiated with a Buy at BTIG
02/27/20 H.C. Wainwright
Viking Therapeutics price target lowered to $18 from $31 at H.C. Wainwright
Options
Axsome Therapeutics call volume above normal and directionally bullish » 13:05
05/01/20
05/01
13:05
05/01/20
13:05
AXSM

Axsome Therapeutics

$87.51 /

-7.5 (-7.89%)

Bullish option flow…

Bullish option flow detected in Axsome Therapeutics with 1,744 calls trading, 1.2x expected, and implied vol increasing over 3 points to 91.21%. May-20 90 calls and May-20 85 calls are the most active options, with total volume in those strikes near 760 contracts. The Put/Call Ratio is 0.13. Earnings are expected on May 8th.

ShowHide Related Items >><<
AXSM Axsome Therapeutics
$87.51 /

-7.5 (-7.89%)

04/28/20 Guggenheim
Axsome Therapeutics price target raised to $200 from $158 at Guggenheim
04/28/20 SunTrust
Axsome Therapeutics price target raised to $200 from $145 at SunTrust
04/28/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $131 from $125 at Cantor Fitzgerald
04/28/20 H.C. Wainwright
Axsome Therapeutics price target raised to $210 from $200 at H.C. Wainwright
Recommendations
Axsome Therapeutics price target raised to $200 from $158 at Guggenheim » 09:25
04/28/20
04/28
09:25
04/28/20
09:25
AXSM

Axsome Therapeutics

$95.00 /

+18.82 (+24.70%)

Guggenheim analyst Yatin…

Guggenheim analyst Yatin Suneja raised the firm's price target on Axsome Therapeutics to $200 from $158 and keeps a Buy rating on the shares. The company's positive Alzheimer's agitation data yesterday show rapid and robust improvement in total CMAI at week five and the overall tolerability profile remains safe, Suneja tells investors in a research note. While some investors may be concerned about the low placebo score in the study, they are in-line with estimated week five placebo responses from the Phase III study in brexpiprazole, adds the analyst. Suneja believes the data "significantly increases" the appeal of AXS-05 and that shares of Axsome remain "significantly undervalued."

ShowHide Related Items >><<
AXSM Axsome Therapeutics
$95.00 /

+18.82 (+24.70%)

04/28/20 SunTrust
Axsome Therapeutics price target raised to $200 from $145 at SunTrust
04/28/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $131 from $125 at Cantor Fitzgerald
04/28/20 H.C. Wainwright
Axsome Therapeutics price target raised to $210 from $200 at H.C. Wainwright
04/27/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $131 from $125 at Cantor Fitzgerald
Recommendations
Axsome Therapeutics price target raised to $200 from $145 at SunTrust » 08:21
04/28/20
04/28
08:21
04/28/20
08:21
AXSM

Axsome Therapeutics

$95.00 /

+18.82 (+24.70%)

SunTrust analyst Joon Lee…

SunTrust analyst Joon Lee raised the firm's price target on Axsome Therapeutics to $200 from $145 and keeps a Buy rating on the shares. The analyst is citing the positive and "highly promising" top line data from the pivotal Phase 2/3 agitation study. Lee anticipates a second confirmatory Phase 3 trial to start after the company's meeting with the FDA, likely in the 2nd half of this year.

ShowHide Related Items >><<
AXSM Axsome Therapeutics
$95.00 /

+18.82 (+24.70%)

04/28/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $131 from $125 at Cantor Fitzgerald
04/28/20 H.C. Wainwright
Axsome Therapeutics price target raised to $210 from $200 at H.C. Wainwright
04/27/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $131 from $125 at Cantor Fitzgerald
04/27/20 Ladenburg
Axsome Therapeutics price target raised to $186 from $165 at Ladenburg
Recommendations
Axsome Therapeutics price target raised to $131 from $125 at Cantor Fitzgerald » 07:34
04/28/20
04/28
07:34
04/28/20
07:34
AXSM

Axsome Therapeutics

$95.00 /

+18.82 (+24.70%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Charles Duncan raised the firm's price target on Axsome Therapeutics to $131 from $125 and keeps an Overweight rating on the shares after Axsome announced positive topline data from its pivotal P2/3 ADVANCE-1 study in Alzheimer's disease agitation, citing reduced clinical risk and enhanced visibility on the significant TAM-expansion opportunity. Duncan tells investors in a research note that the statistically significant efficacy of AXS-05 compared to bupropion and placebo at week-3 and beyond demonstrate a clear drug effect and efficacy for an indication that has no approved treatment options and has generated mixed results for previous Neuro-Innovators.

ShowHide Related Items >><<
AXSM Axsome Therapeutics
$95.00 /

+18.82 (+24.70%)

04/28/20 H.C. Wainwright
Axsome Therapeutics price target raised to $210 from $200 at H.C. Wainwright
04/27/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $131 from $125 at Cantor Fitzgerald
04/27/20 Ladenburg
Axsome Therapeutics price target raised to $186 from $165 at Ladenburg
04/27/20 William Blair
Axsome could have 'a better Abilify' with AXS-05, says William Blair
Recommendations
Axsome Therapeutics price target raised to $210 from $200 at H.C. Wainwright » 07:11
04/28/20
04/28
07:11
04/28/20
07:11
AXSM

Axsome Therapeutics

$95.00 /

+18.82 (+24.70%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on Axsome Therapeutics to $210 from $200 and keeps a Buy rating on the shares after AXS-05 met both primary and secondary endpoints in the Phase 2b/3 trial testing the drug in Alzheimer's disease patients suffering from agitation. There are currently no FDA approved treatments for Alzheimer's agitation, Selvaraju tells investors in a research note. The analyst increased the probability of approval for AXS-05 in the Alzheimer's agitation indication to 70% from 50%.

ShowHide Related Items >><<
AXSM Axsome Therapeutics
$95.00 /

+18.82 (+24.70%)

04/27/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $131 from $125 at Cantor Fitzgerald
04/27/20 Ladenburg
Axsome Therapeutics price target raised to $186 from $165 at Ladenburg
04/27/20 William Blair
Axsome could have 'a better Abilify' with AXS-05, says William Blair
04/27/20 SunTrust
Axsome Therapeutics price target raised to $200 from $145 at SunTrust

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.